Literature DB >> 9924431

Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up.

P Lipponen1, S Aaltoma, V M Kosma, M Ala-Opas, M Eskelinen.   

Abstract

The expression of the standard CD44 (CD44s) and its v6 isoform (CD44v6) was analysed immunohistochemically in 173 cases of transitional cell bladder cancer. The results of immunohistochemical analyses were related to established prognostic factors and clinical follow-up data. The expression intensity of CD44s in non-basal tumour cells was significantly related to TN classification, S-phase fraction (SPF), mitotic index, grade, density of tumour infiltrating lymphocytes. The expression intensity of CD44v6 in non-basal tumour cells was inversely related to DNA ploidy, SPF, and mitotic index. The expression intensity of CD44v6 in basal tumour cells was also inversely related to T-category, grade, papillary status, DNA ploidy, SPF, and mitotic index. Strong expression of CD44s in non-basal tumour cells was related to unfavourable outcome in univariate analysis (p = 0.008), whereas the strong expression of CD44v6 in both non-basal cells (p = 0.005) and basal cells (p = 0.0008) was related to high survival probability. In multivariate survival analysis, the expression intensity of CD44v6 was independently related to favourable outcome in muscle invasive tumours, while in superficial tumours, CD44s was an independent prognostic factor. The results suggest that the expression of CD44s and CD44v6 is associated with malignant features and prognosis in bladder cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9924431     DOI: 10.1002/(SICI)1096-9896(1998100)186:2<157::AID-PATH169>3.0.CO;2-M

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  16 in total

1.  Relation of stem cell markers ALDH1 and CD44 with clinicopathological factors in urothelial carcinomas of urinary bladder.

Authors:  Serkan Senol; Asif Yildırım; Ibrahim Akalin; Fatih Uruç; Bengü Çobanoğlu; Sarenur Yilmaz; Bahar Ceyran; Duygu Kösemetin; Dilek Ece; Abdullah Aydın
Journal:  Int J Clin Exp Med       Date:  2015-03-15

2.  [Use of marker systems in the treatment of bladder cancer].

Authors:  M Burger; F Vom Dorp
Journal:  Urologe A       Date:  2011-03       Impact factor: 0.639

3.  Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carcinoma.

Authors:  V Toma; D Hauri; U Schmid; D Ackermann; R Maurer; G Alund; H Knönagel; M Rist; T C Gasser; G Sauter; J Roth
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

4.  CD44 standard form expression as a predictor of progression in high risk superficial bladder tumors.

Authors:  N E Stavropoulos; I Filliadis; E Ioachim; M Michael; E Mermiga; K Hastazeris; U O Nseyo
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

5.  Relationship of PCNA, C-erbB2 and CD44s expression with tumor grade and stage in urothelial carcinomas of the bladder.

Authors:  Ayhan Yıldırım; Mustafa Kösem; Ilyas Sayar; Ibrahim Gelincik; Alparslan Yavuz; Aliseydi Bozkurt; Unal Erkorkmaz; Irfan Bayram
Journal:  Int J Clin Exp Med       Date:  2014-06-15

6.  Expression of CD44v6 is an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma.

Authors:  Midori Shiozaki; Hideyuki Ishiguro; Yoshiyuki Kuwabara; Masahiro Kimura; Akira Mitsui; Yasuhiro Naganawa; Takahiro Shibata; Yoshitaka Fujii; Hiromitsu Takeyama
Journal:  Oncol Lett       Date:  2011-03-08       Impact factor: 2.967

7.  Effect of CD44 gene polymorphisms on risk of transitional cell carcinoma of the urinary bladder in Taiwan.

Authors:  Wei-Chun Weng; Yu-Hui Huang; Shun-Fa Yang; Shian-Shiang Wang; Wu-Hsien Kuo; Chao-Wen Hsueh; Ching-Hsuan Huang; Ying-Erh Chou
Journal:  Tumour Biol       Date:  2015-12-12

8.  Prognostic significance of CD44s expression in resected non-small cell lung cancer.

Authors:  Yoon Ho Ko; Hye Sung Won; Eun Kyoung Jeon; Sook Hee Hong; Sang Young Roh; Young Seon Hong; Jae Ho Byun; Chan-Kwon Jung; Jin Hyoung Kang
Journal:  BMC Cancer       Date:  2011-08-07       Impact factor: 4.430

9.  Pathobiology and chemoprevention of bladder cancer.

Authors:  Takuji Tanaka; Katsuhito Miyazawa; Tetsuya Tsukamoto; Toshiya Kuno; Koji Suzuki
Journal:  J Oncol       Date:  2011-09-15       Impact factor: 4.375

10.  Evaluation of a triple combination of cytokeratin 20, p53 and CD44 for improving detection of urothelial carcinoma in urine cytology specimens.

Authors:  Brent Arville; Emily O'Rourke; Fai Chung; Mahul Amin; Shikha Bose
Journal:  Cytojournal       Date:  2013-12-27       Impact factor: 2.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.